. 2021 Nov;25(11):1226–1231. doi: 10.5005/jp-journals-10071-23919

Table 5.

Clinical variables comparison of study participants

Clinical variables	Comparison of clinical variables N (%)	p value
	CKD stage 3 vs 4 19 (6.9)^a vs 96 (35.2)^a	0.0617
DDIs identified in patients with different stages of CKD	CKD stage 3 vs 5 19 (6.9)^a vs 158 (57.9)^a	0.0019^*
	CKD stage 4 vs 5 96 (35.2)^a vs 158 (57.9)^a	0.0456^*
Patients with >5 numbers of comorbidities	A vs B 49 (64.4)^b vs 2 (13.3)^b	0.0003^*
Patients who received >7 numbers of medications	A vs B 74 (97.3)^b vs 6 (40)^b	<0.0001^*

DDIs, drug–drug interactions; CKD, chronic kidney disease;

The total number of drug interactions (N = 273) was considered for calculating percentages;

Patient number in each study group was considered as the total number (group A: N = 76, group B: N = 15) for calculating percentages;

Significant at p <0.05